



Case Report

A novel mutation in *CYP17A1* gene leads to congenital adrenal hyperplasia: A case report

Majid Nazari¹ M.Sc., Mohammad Yahya Vahidi Mehrjardi² Ph.D., Nosrat Neghab³ M.D., Mahdi Aghabagheri⁴ M.Sc., Nasrin Ghasemi⁵ M.D., Ph.D.

¹Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

²Medical Genetics Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

³Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁴Meybod Nursing School, Yazd, Iran.

⁵Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Majid Nazari, Mohammad
Yahya Vahidi Mehrjardi are
both first authors

Corresponding Author:

Nasrin Ghasemi;
Abortion Research Centre,
Reproductive Sciences
Institute, Bouali Ave;
Safaeyeh, Yazd, Iran.
Email: n479g@yahoo.co.uk
Tel: (+98) 9133554375
Postal Code: 8916877391

Received 18 June 2018

Revised 2 September 2018

Accepted 26 December 2018

Abstract

Background: Congenital adrenal hyperplasia is a rare autosomal recessive disorder where the mutation in P450 family 17 subfamily A member 1 gene (*CYP17A1*) is involved in its etiology. The disorder represents itself with low blood levels of estrogens, androgens, and cortisol that generally couples with hypertension, Hypokalemia, sexual primary amenorrhea, infantilism and in affected individuals.

Case: In this study, the *CYP17A1* gene in a 14-year-old female was examined. The karyotype of the patient was 46, XX, and the analysis of the *CYP17A1* gene by Sanger sequencing revealed a novel homozygous deletion c.1052-1054CCT which led to isolated 17,20-lyase deficiency.

Conclusion: In conclusion, this study report an in-frame deletion which results in isolated 17, 20-lyase deficiency, and the mutation might be used for diagnosis in other patients with distinctive clinical symptoms.

Key words: Congenital adrenal hyperplasia (CAH), *CYP17A1* gene, Ambiguous genitalia.

Production and Hosting by
Knowledge E

© Majid Nazari et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editor-in-Chief:
Aflatoonian Abbas M.D.

OPEN ACCESS

1. Introduction

Congenital adrenal hyperplasia (CAH) is a group of rare disorders demonstrated by a failure in one of the five enzymes responsible for cortisol production in autosomal recessive pattern (1). In adrenal glands, Pregnenolone is made from cholesterol which later can be processed to either mineralocorticoids or glucocorticoids or to sex steroids in adrenals and gonads (2).

The p450c17 enzyme is encoded by the *CYP17A1* gene located on 10q24.3 (3) and spans 6.6 kb, which comprises eight exons (4). "This gene transcribes 2.1-kb mRNA molecule, which expresses in both the adrenals and gonads and generates a 57-kDa microsomal cytochrome P450c17 enzyme. The *CYP17A1* enzyme catalyzes both steroid 17-hydroxylase and 17,20-lyase activities" (5). Enzymatic failure of the P450c17 enzyme leads to both glucocorticoids and sex steroids deficiencies. After a reduction in blood glucocorticoids levels due to P450c17 defect, anterior pituitary tries to compensate for the insufficiency of glucocorticoids levels by producing extra Adrenocorticotrophic hormone (ACTH). This results in the extra generation of steroid precursors and elevated ACTH level, which leads to some *Congenital* adrenal hyperplasia and result in hypertension, hypokalemia, and a suppressed renin-angiotensin system (6, 7). Moreover, due to the impairments in *CYP17A1*, the mineralocorticoid precursors (corticosterone and 11-deoxycorticosterone) accumulate, which demonstrate glucocorticoid activity, therefore defect in P450c17 does not associate with adrenal crisis, rather than other CAH variants (8). Mutations in the *CYP17A1* gene are the rarest defects in CAH that yields to steroid 17-hydroxylase and 17,20-lyase deficiencies (9). Several mutations in the *CYP17* gene have been reported that cause either complete or combined 17-hydroxylase/17,20-lyase or isolated 17, 20-lyase enzyme deficiencies (10-14).

The purpose of this study was to investigate the molecular defects in *CYP17A1* gene and its relationship with Congenital adrenal hyperplasia.

2. Case presentation

A 14-year-old female, the first child of consanguineous parents with normal family history was referred to the genetic clinic with high blood pressure, ambiguous genitalia, and lack of pubertal development. The blood sample was taken after receiving written informed consent from her parents. No pubic or axillary hair was seen by physical examination, and she had no clinical symptoms of Turner syndrome with 46, XX karyotype. In the sonographic survey, uterus was infantile. She was hypertensive (150/90 mmHg, 50th percentile for age) with high gonadotropins levels (LH, 19 mU/mL; FSH, 34 mU/mL). Moreover, low peripheral concentrations of sex steroids were seen (Table I).

2.1. Sequencing of *CYP17A1* gene

Genomic DNA was purified from peripheral blood leukocytes (PBL) using QIAGEN Mini Blood kit. All the exons of *CYP17A1* gene were proliferated by PCR (primers listed in Table II), which were designed with Primer3 software (<http://primer3.sourceforge.net>). All the PCR products were sequenced in both directions by sanger sequencing.

2.2. Mutational analysis

As shown in Figure 1, a new in-frame homozygous deletion c.1052-1054CCT in exon 6 was identified that reported for the first time. 17 α -hydroxylase deficiency was first pronounced by Biglieri and colleagues (15), who was phenotypically female and presented with sexual infantilism, primary amenorrhea and hypertension.

Table I. Clinical and hormonal characteristics


| | |
|-------------------------------------|--------|
| Blood pressure (mmHg) | 150/90 |
| Karyotype | 46,XX |
| Tanner stage (breast/pubes hair) | B1P1 |
| ACTH (0-60 pg/mL) | 76 |
| Cortisol (5-25 µg/dL) | 17 |
| LH (Female, 12-18 yr: 0.1-10 mU/mL) | 19 |
| FSH (Female, 12-18 yr: 0.3-9 mU/mL) | 34 |
| Estradiol (30-120 pg/mL) | 15 |
| DHEA (350-4300 ng/mL) | 52 |
| Progesterone (0.1-1.3 ng/mL) | 4.6 |

Table II. Primers for *CYP17A1* amplification

| Exon | Primers | Sequences (5'-3') | Areas | Product size (bp) |
|------|---------|----------------------|-----------|-------------------|
| 1 | 1F | CACTGCTGTCTATCTTGCC | 1802-2277 | 476 |
| | 1R | CCTTCACATCATCCCACTA | | |
| 2 | 2F | AGGGACCAGAGGTGTAAG | 3730-4070 | 341 |
| | 2R | GCAGCAGTAGCCAAGAA | | |
| 3 | 3F | AGGGTGCTGATTCATTTC | 4132-4544 | 413 |
| | 3R | GCAGAGGAGGTAGAGGTG | | |
| 4 | 4F | CGCTTGATGTTTGATTGA | 4819-5214 | 396 |
| | 4R | CACCCTGCTCTTGTGATT | | |
| 5 | 5F | ACAGAAGTATGGCAGGAGT | 5776-6289 | 514 |
| | 5R | CCAGAGTAGGTTGGAGGT | | |
| 6 | 6F | ACTGGGAAGGGACTGGA | 6182-6496 | 315 |
| | 6R | GGCTAGATGTCACTGGGAG | | |
| 7 | 7F | AGTGGGAATGAGGGAGTA | 7244-7599 | 356 |
| | 7R | GTCAACAGGTCGGTATAGTT | | |
| 8 | 8F | TCAACCAGGGCAGAACC | 7914-8359 | 446 |
| | 8R | GGAAGAATGGCGGAGAA | | |

F: Forward

R: Reverse



17 α -hydroxylase and 17, 20-lyase deficiencies are rare types of CAH which make up ~1% of all CAH patients (16). "In general, the majority of patients with CAH present with hypertension and primary gonadal failure during adolescence and adulthood, however, a few individuals are reported to be normotensive at the time of diagnosis" (7, 9). The deficiency of 17 α -hydroxylase is a rare reason of CAH, with little more than 100 cases reported (17). 17 α -hydroxylase deficiency was first described in a 35-year-old patient in 1966 by Biglieri and co-workers, who was phenotypically female and presented with hypertension, sexual infantilism, and primary amenorrhea. In the complete deficiency of *CYP17A1*(CDC), the hormonal alterations are summed up as sex steroids and cortisol insufficiencies with mineralocorticoids excessiveness. All afflicted individuals were born with sexual infantilism and incapable of secondary sexual

Symptoms can be briefly listed as hypertension, primary amenorrhea, and ambiguous genitalia. In this case, unlike CDC, the levels of most 17-hydroxysteroids were elevated, suggesting exclusive impairment of ILD. Moreover, the level of cortisol as opposed to in CDC patients exists in the normal range which further rules out the

impairment of 17-hydroxylase activity. The alteration in 351Leu which lies in the redox partner-binding domain of P450c17 leads to an impairment in lyase activity of P450c17 (14, 19), in other words, disrupt interactions of redox partner proteins with CYP17A1.

In sum, this case manifested typical feature of 17 α -hydroxylase and 17,20-lyase deficiencies (e.g., hypertension and ambiguous genitalia). This study is the first paper to report an in-frame deletion which results in isolated 17, 20-lyase deficiency, and this mutation might be used for diagnosis in other patients with distinctive clinical symptoms. Identification of 17 α -hydroxylase/17,20 lyase deficiency was confirmed by the particular profile of adrenal steroid levels, and further confirmation by CYP17A mutation analysis.

Acknowledgments

Our research group thanks the patients and their families for their cooperation.

Conflict of Interest

The authors declare no conflict of interest.

References

- [1] Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Ann Intern Med* 2002; 136: 320–334.
- [2] DeVore NM, Scott EE. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. *Nature* 2012; 482: 116–119.
- [3] Matteson KJ, Picado-Leonard J, Chung BC, Mohandas TK, Miller WL. Assignment of the gene for adrenal p450c17 (steroid 17 α -hydroxylase/17, 20 lyase) to human chromosome 10. *J Clin Endocrinol Metab* 1986; 63: 789–791.
- [4] Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 α -hydroxylase/17, 20 lyase): similarity with the gene for P450c21. *DNA* 1987; 6: 439–448.
- [5] Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE, et al. Cytochrome P450c17 (steroid 17 α -hydroxylase/17, 20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. *Proc Natl Acad Sci USA* 1987; 84: 407–411.
- [6] Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev* 2011; 32: 81–151.
- [7] Yanase T, Simpson ER, Waterman MR. 17 α -hydroxylase/17, 20-lyase deficiency: from clinical investigation to molecular definition. *Endocr Rev* 1991; 12: 91–108.
- [8] Krone N, Dhir V, Ivison HE, Arlt W. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. *Clin Endocrinol* 2007; 66: 162–172.
- [9] Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. *Endocrinol Metab Clin North Am* 2001; 30: 101–119.
- [10] Biason-Lauber A, Leiberman E, Zachmann M. A single amino acid substitution in the putative redox partner-binding site of P450c17 as cause of isolated 17, 20-lyase deficiency. *J Clin Endocrinol Metab* 1997; 82: 3807–3812.
- [11] Sherbet DP, Tiosano D, Kwist KM, Hochberg Z, Auchus RJ. CYP17 mutation E305G causes isolated 17, 20-lyase deficiency by selectively altering substrate binding. *J Biol Chem* 2003; 278: 48563–48569.
- [12] Turkkahraman D, Guran T, Ivison H, Griffin A, Vijzelaar R, Krone N. Identification of a novel large CYP17A1 deletion by MLPA analysis in a family with classic 17 α -hydroxylase deficiency. *Sex Dev* 2015; 9: 91–97.
- [13] Brooke AM, Taylor NF, Shepherd JH, Gore ME, Ahmad T, Lin L, et al. A novel point mutation in P450c17 (CYP17) causing combined 17 α -hydroxylase/17, 20-lyase deficiency. *J Clin Endocrinol Metab* 2006; 91: 2428–2431.
- [14] van Den Akker EL, Koper JW, Boehmer AL, Themmen AP, Verhoef-Post M, Timmerman MA, et al. Differential inhibition of 17 α -hydroxylase and 17, 20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. *J Clin Endocrinol Metab* 2002; 87: 5714–5721.
- [15] Oh YK, Ryoo U, Kim D, Cho SY, Jin DK, Yoon BK, et al. 17 α -hydroxylase/17, 20-lyase deficiency in three siblings with primary amenorrhea and absence of secondary sexual development. *J Pediatr Adolesc Gynecol* 2012; 25: e103–e105.
- [16] Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. *J Clin Invest* 1966; 45: 1946–1954.
- [17] Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 8th Ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
- [18] Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. *J Clin Endocrinol Metab* 2012; 97: 507–516.
- [19] Geller DH, Auchus RJ, Mendonça BB, Miller WL. The genetic and functional basis of isolated 17, 20-lyase deficiency. *Nat Genet* 1997; 17: 201–205.
- [20] Hershkovitz E, Parvari R, Wudy SA, Hartmann MF, Gomes LG, Loewental N, et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17, 20-lyase deficiency. *J Clin Endocrinol Metab* 2008; 93: 3584–3588.

- [21] Kok RC, Timmerman MA, Wolffenbuttel KP, Drop SL, de Jong FH. Isolated 17, 20-lyase deficiency due to the cytochrome b5 mutation W27X. *J Clin Endocrinol Metab* 2010; 95: 994–999.